middle.news
Healius Eyes Agilex Sale Amid Rising Pathology Costs and Budget Freeze
8:42am on Wednesday 13th of May, 2026 AEST
•
Healthcare
Read Story
Healius Eyes Agilex Sale Amid Rising Pathology Costs and Budget Freeze
8:42am on Wednesday 13th of May, 2026 AEST
Key Points
FY26 EBITDA guidance narrowed to $259m-$264m
Pathology volumes mixed; revenue growth modest
Fair Work Commission ruling adds $1.8m Q4 cost
Agilex Biolabs revenue up 13.7%, sale process underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Healius (ASX:HLS)
OPEN ARTICLE